Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2156340
Abstract: ABSTRACT Introduction Lenvatinib was the first drug approved in 2017 for first-line treatment of hepatocarcinoma (HCC) after 10 years of Sorafenib as exclusive standard of care. The therapeutic armamentarium has recently expanded following the approval… read more here.
Keywords: five years; hepatocellular carcinoma; lenvatinib hepatocellular; carcinoma predictive ... See more keywords